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Much progress has been made in identifying the factors that cause tumor formation. Yet, how cancer cells leave
primary tumors to colonize distant organs—a process called metastasis—is still poorly understood. Here we
discuss recent advances that describe factors that promote the invasive ability of cancer cells.
Metastasis Finds a Microhelper
MicroRNAs (miRNAs) have emerged as key regulators of many biological processes, both normal (such as develop-
ment) and abnormal (such as tumor formation). Now, Ma et al. (2007) reveal that miRNAs also promote the metas-
tasis of cancer cells. They examined 29 miRNAs known to have altered expression in primary breast carcinomas
compared with normal mammary tissue and homed in on miR-10b because it is highly expressed in certain meta-
static breast cancer cells. Remarkably, silencing of this miRNA reduced the ability of the breast cancer cells to
undergo one of the hallmarks of metastasis—invasion through an artificial matrix; in contrast, overexpression of
miR-10b increased the motility and invasiveness of these cells. To analyze miR-10b’s effects on metastasis in vivo,
Ma et al. overexpressed miR-10b in nonmetastatic human breast cancer cells and implanted these cells into the
mammary fat pads of immunodeficient mice. Unlike the control nonmetastatic human breast cancer cells that
formed noninvasive tumors, the cells overexpressing miR-10b invaded the stroma, muscles, and vasculature and
were able to metastasize to distant sites such as the lung. This metastatic switch involves some of the same tran-
scription factors that control the epithelial-to-mesenchymal transition (EMT) during development. Ma et al. observed
that ectopic expression of the EMT-promoting transcription factor Twist increased the amount of miR-10b in human
mammary epithelial cells. This effect is probably direct as Twist binds to the promoter of miR-10b. Silencing of
miR-10b in cells overexpressing Twist reduced the mobility and invasiveness of these cells. To identify the mRNA
targets of miR-10b, Ma et al. used a computational strategy. This approach identified HOXD10 mRNA (HOXD10
is known to suppress expression of genes involved in cell migration and in remodeling of the extracellular matrix)
as a potential target of miR-10b. Overexpression of miR-10b reduced the amount of HOXD10 protein and caused
increased expression of the gene RHOC, which is well-known to be important in metastasis and is repressed by
HOXD10. To determine whether miR-10b expression correlates with clinical outcome, Ma et al. analyzed primary
tumor samples from patients with breast cancer. Interestingly, 50% of patients with metastatic breast cancer had
increased expression of miR-10b in their primary tumors. This study furthers our understanding of how cancer cells
move beyond the primary tumor and implicates small RNAs in the regulation of this process.
L. Ma et al. (2007). Nature 449, 682–688. Published online September 26, 2007. 10.1038/nature06174.
Stem Cells Help Cancer Cells to Set up Shop
Bone-marrow-derived mesenchymal stem cells (MSCs),
which are pluripotent progenitors, are recruited to the
stroma of developing tumors, but it is not known how
these cells contribute to tumorigenesis. Karnoub et al.
(2007) now show that these stem cells promote the metas-
tasis of breast tumor cells. In this study, these authors ob-
served that murine MSCs become localized to neoplastic
sites established by human breast cancer xenografts.
They also showed that cultured MSCs derived from hu-
man bone marrow migrate toward media derived from
breast cancer cells. Furthermore, human MSCs labeled
with green fluorescent protein become localized at sites
of human breast cancer xenografts in mice. To determine
how these MSCs contribute to breast cancer, the authors mixed MSCs with breast cancer cells and injected them
into immunocompromised mice. The presence of the MSCs increased the metastatic potential of the breast cancer
cells. Interestingly, the ability of MSCs to promote metastasis only occurred when the MSCs were in close proximity
to the breast cancer cells. To identify local paracrine cues that MSCs may provide to promote metastasis, the au-
thors analyzed media derived from cocultures of breast cancer cells and MSCs and discovered that expression
of the cytokine CCL5 by the MSCs was induced 60-fold. Forced overexpression of CCL5 by breast cancer cells
did not affect primary tumor growth but did enhance late steps in the invasion-metastasis cascade. In fact, CCL5
appears to help cancer cells to colonize distant sites by enhancing their motility. The receptor for CCL5 is CCR5
and is expressed by breast cancer cells but not by the MSCs. Indeed, decreasing the expression of CCR5 in breast
cancer cells abrogated the boost in metastatic potential conferred by MSCs. Isolation and injection of metastasized
cancer cells (that had been induced by the presence of MSCs) into naı¨ve recipient mice resulted in primary tumor
formation, but importantly, these cell no longer showed the increased ability to promote metastasis. These findings
Breast cancer xenografts in mice metastasize (green) more
to the lung in the presence (right) but not the absence of
(left) stromal mesenchymal stem cells. Image courtesy of
A. Karnoub.Cell 131, November 2, 2007 ª2007 Elsevier Inc. 425
support the notion that certain cancer cells metastasize in response to signals from the tumor stroma and that
preventing this response or blocking the signals directly could prevent metastasis.
A.E. Karnoub et al. (2007). Nature 449, 557–563.
Nesting in Another Location
The intermediate filament protein Nestin is a marker for both cancer cells and stem/progenitor cells. Focusing on
a subset of prostate cancer cells that are resistant to androgen deprivation therapy, Kleeberger et al. now show
that Nestin is important for the migration and invasiveness of these cells. First, they showed that Nestin expression
was extremely high in prostate cancer cell lines and in clinical tissue samples, particularly those that were resistant to
androgen deprivation therapy. Next, they observed that a reduction in Nestin expression blocked two characteristics
of metastatic cells: cell motility and the ability to penetrate a collagen matrix. Furthermore, in highly metastatic rodent
prostate cancer cell lines, the authors found that Nestin was enriched in metastatic deposits. The authors then
lowered Nestin expression in these highly metastatic cells and introduced them into mice. They found that these
Nestin-deficient tumors had a decreased number of metastases. It will be interesting to determine how Nestin
intersects with the cellular pathways that are known to promote metastasis of tumor cells.
W. Kleeberger et al. (2007). Cancer Res. 67, 9199–9206.
A New Twist in Metastasis
Many aspects of the metastasis of epithelial tumors are reminiscent of the epithelial-to-mesenchymal transition
(EMT) that occurs during development. Lo et al. (2007) now report that cancer cells of epithelial origin (such as those
of breast and pancreas) adopt a more mesenchymal-like state when exposed to two ligands of the EGF receptor
(EGFR), EGF and TGF-a. By examining the expression of genes important in adopting a mesenchymal fate, the au-
thors found that expression of the transcription factor TWIST was upregulated in epithelial tumors treated with EGFR
ligands. By treating tumor cells with a panel of inhibitors to different pathways downstream of EGFR, Lo et al. dis-
covered that an inhibitor of STAT transcription factors prevented the upregulation of TWIST after exposure of the
tumor cells to EGFR ligands. The transcription factor STAT3 is known to act downstream of EGFR, and the authors
reveal that STAT3 is required for activation of the promoter of the human TWIST gene in epithelial tumor cells treated
with EGFR ligands. Moreover, STAT3 when localized to the nucleus binds directly to the human TWIST promoter.
Thus, the EGFR pathway induces STAT-dependent upregulation of TWIST to promote EMT in tumor cells, which
is a key step towards metastasis.
H.-W. Lo et al. (2007). Cancer Res. 67, 9066–9076.
Cancer Cells Get a Grip on Their Environment
The small GTPase Rab25 is known to promote the invasiveness of ovarian
and breast tumors. Caswell et al. (2007) provide a potential explanation for
this phenomenon by identifying and characterizing a direct molecular inter-
action between the GTP-bound form of Rab25 and the b1 subunit of a5b1
integrin. The invasiveness of Rab25-expressing cells migrating through
a 3D matrix was augmented by the presence of fibronectin (the predominant
ligand of a5b1) in the matrix and was dependent on the fibronectin-integrin
interaction. When ovarian cancer cells expressing Rab25 migrated on a ma-
trix of fibrillar collagen and fibronectin, they extended pseudopodia, whereas
control cancer cells did not. Using fluorescence lifetime imaging microscopy,
the authors showed that on this fibrillar matrix, the association between
Rab25 and b1 was enhanced in the pseudopodia. High-resolution timelapse
fluorescence microscopy revealed that in the absence of Rab25, a5 was lo-
calized to the plasma membrane, whereas in the presence of Rab25 both b1
and Rab25 became localized to the tips of pseudopodia in slowly moving
vesicles. The use of photoactivatable integrin probes and timelapse micros-
copy then showed that the slowly moving vesicles containing Rab25 contin-
uously delivered a5b1 to the tips of pseudopodia and enhanced the rapid
cycling of a spatially restricted population of integrin heterodimers within
this subcellular locale. Thus, Rab25 may promote invasion of tumor cells
by directing integrin-mediated migration through the extracellular matrix.
P.T. Caswell et al. (2007). Dev. Cell. 13, 496–510.
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(Left to right) Time course (20 s intervals)
of a5b1 integrin (green) delivery from
a Rab25 (red) vesicle to the tip of an
advancing pseudopod during migration
of an ovarian tumor cell on a 3D matrix.
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